What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Surgery and Chemotherapy.
His Breast cancer research is multidisciplinary, relying on both Primary tumor and Lymph node.
He interconnects Trastuzumab, Antiestrogen, Tamoxifen, Gynecology and Prospective cohort study in the investigation of issues within Oncology.
His Surgery study integrates concerns from other disciplines, such as Gastroenterology, Mastectomy, Metastasis and Anthracycline.
His Chemotherapy research includes elements of Radiation therapy and Mammary gland.
In his research on the topic of Cancer, Hazard ratio is strongly related with Proportional hazards model.
His most cited work include:
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy (1133 citations)
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer (975 citations)
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy (852 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Breast cancer, Oncology, Chemotherapy and Surgery are his primary areas of study.
Cancer, Metastatic breast cancer, Tamoxifen, Cyclophosphamide and Anastrozole are subfields of Internal medicine in which his conducts study.
His Breast cancer research incorporates themes from Stage, Radiation therapy and Survival rate.
His Oncology study which covers Trastuzumab that intersects with Epirubicin.
He has researched Chemotherapy in several fields, including Gastroenterology, Mastectomy and Mammary gland.
Aman U. Buzdar works mostly in the field of Surgery, limiting it down to topics relating to Carcinoma and, in certain cases, Breast carcinoma, as a part of the same area of interest.
He most often published in these fields:
- Internal medicine (77.52%)
- Breast cancer (64.00%)
- Oncology (61.33%)
What were the highlights of his more recent work (between 2008-2021)?
- Internal medicine (77.52%)
- Breast cancer (64.00%)
- Oncology (61.33%)
In recent papers he was focusing on the following fields of study:
Aman U. Buzdar mostly deals with Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer.
The various areas that Aman U. Buzdar examines in his Internal medicine study include Gynecology and Surgery.
Aman U. Buzdar regularly ties together related areas like Paclitaxel in his Breast cancer studies.
Aman U. Buzdar studied Oncology and Metastatic breast cancer that intersect with Confidence interval.
His Chemotherapy research includes themes of Gastroenterology and Logistic regression.
His Cancer research is multidisciplinary, relying on both Disease and Cohort.
Between 2008 and 2021, his most popular works were:
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen (628 citations)
- Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review (582 citations)
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer (529 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Aman U. Buzdar mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Trastuzumab.
Internal medicine connects with themes related to Gynecology in his study.
His research integrates issues of Surgery, Chemotherapy and Hazard ratio in his study of Breast cancer.
His research investigates the connection between Surgery and topics such as Taxane that intersect with problems in Concomitant, Adjuvant therapy and Fluorouracil.
His work in Oncology tackles topics such as Survival rate which are related to areas like Prospective cohort study.
His research in the fields of Breast disease and Metastatic breast cancer overlaps with other disciplines such as Neuropsychology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
